Edgewise Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
EWTX$46.53-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three months ended March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities · · · · · | ||||||
| Net loss | | $(49,013) | | $(40,798) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation | | | 537 | | 513 | |
| Stock-based compensation | | 8,715 | | 9,059 | ||
| Accretion of discount on marketable securities, net | | | (1,013) | | | (1,923) |
| Amortization of right-of-use asset | | | 53 | | | 41 |
| Changes in assets and liabilities: | | | | | ||
| Prepaid expenses and other assets | | 3,045 | | (1,478) | ||
| Accounts payable | | 1,446 | | 2,858 | ||
| Accrued compensation | | (6,752) | | (6,081) | ||
| Accrued other expenses and other liabilities | | 635 | | 122 | ||
| Lease liability | | (196) | | | (179) | |
| Net cash used in operating activities | | (42,543) | | | (37,866) | |
| | | | | | | |
| Cash flows from investing activities | | | | | | |
| Purchases of marketable securities | | (110,152) | | (122,180) | ||
| Sales of marketable securities | | | 3,966 | | | 15,000 |
| Maturities of marketable securities | | | 108,879 | | | 151,122 |
| Purchases of property and equipment | | (260) | | (44) | ||
| Net cash provided by investing activities | | 2,433 | | 43,898 | ||
| | | | | | | |
| Cash flows from financing activities | | | | | ||
| Exercise of stock options | | 12,173 | | 2,261 | ||
| Payment of deferred offering costs | | | — | | | (38) |
| Net cash provided by financing activities | | 12,173 | | 2,223 | ||
| | | | | | | |
| Net change in cash and cash equivalents | | (27,937) | | 8,255 | ||
| Cash and cash equivalents at beginning of period | | 61,148 | | 41,666 | ||
| Cash and cash equivalents at end of period | | $33,211 | | $49,921 | ||
| Supplemental disclosures of non-cash investing and financing activities: | | | | | ||
| Property and equipment purchases included in accounts payable and accrued other expenses | | $41 | | $— | ||
| Deferred offering costs included in accounts payable and accrued other expenses | | $— | | $395 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.